Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | YAP1 | P46937 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20521517 | 0.86 | KMT2A (0.43) | MAPTNPSR1GRM5NPC1ALDH1A1 | |
| SCHEMBL20521472 | 0.84 | NPSR1 (0.43) | MAPTNPSR1GRM5NPC1ALDH1A1 | |
| SCHEMBL20521818 | 0.83 | GPR119 (0.37) | ALDH1A1LMNAGPR119 | |
| SCHEMBL8221363 | 0.78 | GPR119 (0.53) | MAPTNPSR1GRM5NPC1ALDH1A1 | |
| SCHEMBL20521670 | 0.76 | NPSR1 (0.43) | MAPTNPSR1GRM5NPC1ALDH1A1 | |
| SCHEMBL20521490 | 0.74 | MAPT (0.45) | MAPTNPSR1GRM5NPC1ALDH1A1 | |
| SCHEMBL20522063 | 0.74 | MAPT (0.45) | MAPTNPSR1GRM5NPC1ALDH1A1 | |
| SCHEMBL20521661 | 0.74 | MAPT (0.45) | MAPTNPSR1GRM5NPC1ALDH1A1 | |
| SCHEMBL20521354 | 0.74 | MAPT (0.45) | MAPTNPSR1GRM5NPC1ALDH1A1 | |
| SCHEMBL8259695 | 0.71 | GPR119 (0.53) | GPR119YAP1SLC2A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2023-05-25 | — | — | US | disclosed |
| EP-4112623-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2023-01-04 | — | — | EP | disclosed |
| EP-3601296-B1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2022-05-25 | — | — | EP | disclosed |
| US-20210198281-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2021-07-01 | — | — | US | disclosed |
| US-10995101-B2 | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers | ITEOS THERAPEUTICS SA (BE) | 2021-05-04 | — | — | US | disclosed |
| EP-3601296-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | Iteos Therapeutics (BE) | 2020-02-05 | — | — | EP | disclosed |
| US-20190276473-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2019-09-12 | — | — | US | disclosed |
| WO-2018178338-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | ITEOS THERAPEUTICS (BE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995101-B2 | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers | ADORA2A, ADORA2B, ADORA3 | MAPT 4099/4885NPSR1 371/4885GRM5 587/4885 |
| US-20190276473-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | ADORA2A, ADORA2B, ADORA3 | MAPT 4099/4885NPSR1 371/4885GRM5 587/4885 |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | ADORA2A, ADORA2B, ADORA3 | MAPT 4099/4885NPSR1 371/4885GRM5 587/4885 |
| US-20210198281-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA3 | MAPT 4099/4885NPSR1 371/4885GRM5 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.